{"id":1602,"date":"2019-04-11T08:00:00","date_gmt":"2019-04-11T08:00:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-ab-uppdaterad-finansiell-kalender\/"},"modified":"2026-02-23T13:18:31","modified_gmt":"2026-02-23T13:18:31","slug":"oncopeptides-ab-uppdaterad-finansiell-kalender","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-uppdaterad-finansiell-kalender\/","title":{"rendered":"Oncopeptides AB: Uppdaterad finansiell kalender"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">Stockholm &#8211; 11 april 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) meddelade idag att man uppdaterat sin finansiella kalender d&auml;r del&aring;rsrapporten f&ouml;r Q2 2019 flyttats till den 28:e augusti.<\/p>\n<p class=\"mfn-wp-retain\">Datumen f&ouml;r kommande rapporter samt &aring;rsst&auml;mma framg&aring;r nedan. Oncopeptides kommer ocks&aring; att h&aring;lla en webcast samma dag som del&aring;rsrapporterna publiceras.<\/p>\n<p><\/strong><\/div>\n<ul>\n<li>&Aring;rsredovisningen f&ouml;r 2018 publiceras mellan den 23 &#8211; 26 april.<\/li>\n<li>Del&aring;rsrapporten f&ouml;r Q1 2019 publiceras den 21 maj, klockan 08.00.<\/li>\n<li>&Aring;rsst&auml;mman f&ouml;r 2018 h&aring;lls den 21 maj och startar klockan 14.00.<\/li>\n<li>Del&aring;rsrapporten f&ouml;r Q2 2019 publiceras den 28 augusti, klockan 08.00.<\/li>\n<li>Del&aring;rsrapporten f&ouml;r Q3 2019 publiceras den 19 november, klockan 08.00.<\/li>\n<li>Bokslutskommunik&eacute;n f&ouml;r 2019 publiceras den 20 februari 2020, klockan 08.00.<\/li>\n<\/ul>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information, kontakta:<\/p>\n<p class=\"mfn-wp-retain\">Rein Piir, Head of Investor Relations f&ouml;r Oncopeptides<br \/>E-post: rein.piir@oncopeptides.com<br \/>Mobil: +46 (0)70 853 72 92<\/p>\n<p class=\"mfn-wp-retain\">Information l&auml;mnades f&ouml;r offentligg&ouml;rande den 11 april 2019 kl.10.00.<\/p>\n<p class=\"mfn-wp-retain\">Om Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">Oncopeptides &auml;r ett l&auml;kemedelsf&ouml;retag som utvecklar l&auml;kemedel f&ouml;r behandling av cancer. Bolaget fokuserar p&aring; utvecklingen av produktkandidaten melflufen, en peptidl&auml;nkad alkylerare, tillh&ouml;rande en ny l&auml;kemedelsklass kallad Peptidase Enhanced Compounds (PEnC). Melflufen utvecklas som en ny behandling av den hematologiska cancersjukdomen multipelt myelom och testas f&ouml;r n&auml;rvarande i en global registreringsgrundade klinisk fas 3-studie samt i tre ytterligare p&aring;g&aring;ende kliniska pr&ouml;vningar. Oncopeptides har huvudkontor i Stockholm och &auml;r noterat i Mid Cap-segmentet p&aring; Nasdaq Stockholm med kortnamn ONCO.<\/p>\n<p class=\"mfn-wp-retain\">Mer information finns p&aring; www.oncopeptides.com.<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2786668%2F1024193.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2786668%2F1024193.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Stockholm &#8211; 11 april 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) meddelade idag att man uppdaterat sin finansiella kalender d&auml;r del&aring;rsrapporten f&ouml;r Q2 2019 flyttats till den 28:e augusti. Datumen f&ouml;r kommande rapporter samt &aring;rsst&auml;mma framg&aring;r nedan. Oncopeptides kommer ocks&aring; att h&aring;lla en webcast samma dag som del&aring;rsrapporterna publiceras. &Aring;rsredovisningen f&ouml;r 2018 publiceras mellan den [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[392,391,393],"class_list":["post-1602","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-ir","mfn-news-tag-news","mfn-news-tag-swedish"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1602"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1602"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}